{"entity":{"id":"nct07572396","kind":"trial","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","aka":[],"tldr":"A phase 2 trial of EGCG and Quinine Sulfate Vaginal Suppository in vaginal cancer, run by Amplexd Therapeutics, Inc., now recruiting.","summary":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities is a phase 2 interventional study registered as NCT07572396 by Amplexd Therapeutics, Inc., with 45 participants planned, started 2026-04-30 and due to reach its primary completion in 2026-12-27. Interventions recorded: EGCG and Quinine Sulfate Vaginal Suppository.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07572396","url":"https://clinicaltrials.gov/study/NCT07572396"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["vaginal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07572396","phase":"2","setting":"A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology","sponsor":"Amplexd Therapeutics, Inc.","enrolled":45,"outcomes":[]},"route":"/trials/nct07572396/","neighbours":{"cancer":[{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"}]}}